Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017)

Stanford University1 site in 1 country219 target enrollmentFebruary 2007

ConditionsLung Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Lung Cancer
Sponsor: Stanford University
Enrollment: 219
Locations: 1
Primary Endpoint: to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells.
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The primary aim of this study is to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients.

Detailed Description

The purpose of this study is to determine whether we can identify lung cancer cells circulating in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells such as CD44 and epithelial specific antigen.

Registry

clinicaltrials.gov

Start Date

February 2007

End Date

July 13, 2021

Last Updated

3 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Stanford University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Inclusion Criteria:Inclusion Criteria (Cases):
•Advanced stage (IIIB with malignant effusion or IV) histologically or cytologically confirmed NSCLC
•Patients must be newly diagnosed (untreated) or have evidence of disease progression at the time of sample collection
•ability to sign informed consent
•at least 18 years of age
•Inclusion Criteria (Controls):
•no known prior or active malignancy
•ability to sign informed consent
•at least 18 years of age

Exclusion Criteria

•history of any other cancer other than non-melanoma skin cancer within the last 5 years Exclusion Criteria:
•history of any other cancer other than non-melanoma skin cancer within the last 5 years
•pregnant women

Outcomes

Primary Outcomes

to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells.

Time Frame: 2 years